Literature DB >> 25687841

Double somatic mosaic mutations in TET2 and DNMT3A--origin of peripheral T cell lymphoma in a case.

Tran B Nguyen1, Mamiko Sakata-Yanagimoto, Rie Nakamoto-Matsubara, Terukazu Enami, Yufu Ito, Toshikata Kobayashi, Naoshi Obara, Yuichi Hasegawa, Shigeru Chiba.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25687841     DOI： 10.1007/s00277-015-2332-0

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  10 in total

1.  BCL6 locus is hypermethylated in angioimmunoblastic T-cell lymphoma.

Authors:  Shoko Nishizawa; Mamiko Sakata-Yanagimoto; Keiichiro Hattori; Hideharu Muto; Tran Nguyen; Koji Izutsu; Kenichi Yoshida; Seishi Ogawa; Naoya Nakamura; Shigeru Chiba
Journal:  Int J Hematol       Date:  2016-12-05       Impact factor: 2.490

Review 2.  Dysregulation of TET2 in hematologic malignancies.

Authors:  Shigeru Chiba
Journal:  Int J Hematol       Date:  2016-11-15       Impact factor: 2.490

Review 3.  Molecular understanding of peripheral T-cell lymphomas, not otherwise specified (PTCL, NOS): A complex disease category.

Authors:  Mamiko Sakata-Yanagimoto; Kota Fukumoto; Kennosuke Karube; Shigeru Chiba
Journal:  J Clin Exp Hematop       Date:  2021-03-15

4.  Identification of cell-type-specific mutations in nodal T-cell lymphomas.

Authors:  T B Nguyen; M Sakata-Yanagimoto; Y Asabe; D Matsubara; J Kano; K Yoshida; Y Shiraishi; K Chiba; H Tanaka; S Miyano; K Izutsu; N Nakamura; K Takeuchi; H Miyoshi; K Ohshima; T Minowa; S Ogawa; M Noguchi; S Chiba
Journal:  Blood Cancer J       Date:  2017-01-06       Impact factor: 11.037

5.  Overlap at the molecular and immunohistochemical levels between angioimmunoblastic T-cell lymphoma and a subgroup of peripheral T-cell lymphomas without specific morphological features.

Authors:  Rebeca Manso; Julia González-Rincón; Manuel Rodríguez-Justo; Giovanna Roncador; Sagrario Gómez; Margarita Sánchez-Beato; Miguel A Piris; Socorro M Rodríguez-Pinilla
Journal:  Oncotarget       Date:  2018-03-01

6.  Droplet digital polymerase chain reaction assay and peptide nucleic acid-locked nucleic acid clamp method for RHOA mutation detection in angioimmunoblastic T-cell lymphoma.

Authors:  Sharna Tanzima Nuhat; Mamiko Sakata-Yanagimoto; Daisuke Komori; Keiichiro Hattori; Yasuhito Suehara; Kota Fukumoto; Manabu Fujisawa; Manabu Kusakabe; Kosei Matsue; Hirotake Wakamatsu; Mitsunobu Shimadzu; Shigeru Chiba
Journal:  Cancer Sci       Date:  2018-03-31       Impact factor: 6.716

7.  Dnmt3b catalytic activity is critical for its tumour suppressor function in lymphomagenesis and is associated with c-Met oncogenic signalling.

Authors:  Katarina Lopusna; Pawel Nowialis; Jana Opavska; Ajay Abraham; Alberto Riva; Rene Opavsky
Journal:  EBioMedicine       Date:  2021-01-05       Impact factor: 8.143

8.  Clinical significance of disease-specific MYD88 mutations in circulating DNA in primary central nervous system lymphoma.

Authors:  Keiichiro Hattori; Mamiko Sakata-Yanagimoto; Yasuhito Suehara; Yasuhisa Yokoyama; Takayasu Kato; Naoki Kurita; Hidekazu Nishikii; Naoshi Obara; Shingo Takano; Eiichi Ishikawa; Akira Matsumura; Yuichi Hasegawa; Shigeru Chiba
Journal:  Cancer Sci       Date:  2017-12-23       Impact factor: 6.716

Review 9.  Review of the biologic and clinical significance of genetic mutations in angioimmunoblastic T-cell lymphoma.

Authors:  Kota Fukumoto; Tran B Nguyen; Shigeru Chiba; Mamiko Sakata-Yanagimoto
Journal:  Cancer Sci       Date:  2017-11-27       Impact factor: 6.518

10.  Genetic evidence implies that primary and relapsed tumors arise from common precursor cells in primary central nervous system lymphoma.

Authors:  Keiichiro Hattori; Mamiko Sakata-Yanagimoto; Manabu Kusakabe; Toru Nanmoku; Yasuhito Suehara; Ryota Matsuoka; Masayuki Noguchi; Yasuhisa Yokoyama; Takayasu Kato; Naoki Kurita; Hidekazu Nishikii; Naoshi Obara; Shingo Takano; Eiichi Ishikawa; Akira Matsumura; Masafumi Muratani; Yuichi Hasegawa; Shigeru Chiba
Journal:  Cancer Sci       Date:  2018-11-18       Impact factor: 6.716
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.